Bio-Techne (TECH) Q3 FY26 earnings call

Bio-Techne navigated a mixed market in Q3 FY26, with strong performance from large pharma and stabilizing U.S. academic demand, but continued softness in emerging biotech. The company experienced a 400 basis point headwind from specific cell therapy and OEM order timing, resulting in a 2% organic revenue decline. Strategic brand alignment and leveraging AI are key initiatives, with a positive outlook for fiscal 2027 as market conditions are expected to normalize and company-specific headwinds abate.